Medical treatment against diabetes reduces Parkinson’s disease risk

A Norwegian study shows that the taking of diabetes medicine reduces the risk of getting Parkinson´s disease.

Researchers at the Department of Clinical Medicine at the University of Bergen (UiB) have discovered that medical treatment against diabetes reduces the risk of getting Parkinson´s disease by 35 per cent.

"We have made an important discovery, which takes us a step further towards solving the Parkinson´s riddle," says researcher Charalampos Tzoulis. He has lead the study together with researcher Kristoffer Haugarvoll at the same department.

One step further

Tzoulis says that the researchers have to do follow-up studies on the diabetes medicine to fully understand why it protects against Parkinson´s disease.

"If we understand the mechanisms behind the protection, then we have a chance to develop a new treatment," Tzoulis says.

Influence the cell´s powerhouse

The researchers believe that the diabetes medicines, containing so-called glitazones, are influencing the cells to produce more mitochondria. Mitochondria are the powerhouse of the cells, transforming nutrients that the cells need to work.

Tzoulis´research group has previously shown that the production of mitochondria decreases during Parkinson´s.

100 million prescriptions

To see the connection between diabetes and Parkinson´s, the researchers analyzed and compared data from the Norwegian Prescription Data Base. The database has stored information on all use of prescription the last 10 years and contains data on more than 100 million prescriptions.

Source: http://www.uib.no/en/med/110489/diabetes-medicine-reduces-parkinson's-risk

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Dual screening for liver fibrosis and retinopathy in type 2 diabetes